Corcept Therapeutics Incorporated HTD.F Stock
Corcept Therapeutics Incorporated Price Chart
Corcept Therapeutics Incorporated HTD.F Financial and Trading Overview
| Corcept Therapeutics Incorporated stock price | 22.07 EUR |
| Previous Close | 21 EUR |
| Open | 21 EUR |
| Bid | 21 EUR x 63700 |
| Ask | 21.2 EUR x 61200 |
| Day's Range | 21 - 21 EUR |
| 52 Week Range | 17.79 - 29.81 EUR |
| Volume | 1 EUR |
| Avg. Volume | 2 EUR |
| Market Cap | 2.19B EUR |
| Beta (5Y Monthly) | 0.494014 |
| PE Ratio (TTM) | 28.767122 |
| EPS (TTM) | 0.88 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.25 EUR |
HTD.F Valuation Measures
| Enterprise Value | 1.65B EUR |
| Trailing P/E | 28.767122 |
| Forward P/E | 21.428572 |
| PEG Ratio (5 yr expected) | -0.64 |
| Price/Sales (ttm) | 5.3004923 |
| Price/Book (mrq) | 4.2892156 |
| Enterprise Value/Revenue | 3.983 |
| Enterprise Value/EBITDA | 16.258 |
Trading Information
Corcept Therapeutics Incorporated Stock Price History
| Beta (5Y Monthly) | 0.494014 |
| 52-Week Change | 7.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 29.81 EUR |
| 52 Week Low | 17.79 EUR |
| 50-Day Moving Average | 21.05 EUR |
| 200-Day Moving Average | 22.51 EUR |
HTD.F Share Statistics
| Avg. Volume (3 month) | 2 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 101.58M |
| Float | 82.97M |
| Short Ratio | N/A |
| % Held by Insiders | 11.59% |
| % Held by Institutions | 83.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 22.83% |
| Operating Margin (ttm) | 24.33% |
| Gross Margin | 98.66% |
| EBITDA Margin | 24.49% |
Management Effectiveness
| Return on Assets (ttm) | 11.59% |
| Return on Equity (ttm) | 20.16% |
Income Statement
| Revenue (ttm) | 413.82M EUR |
| Revenue Per Share (ttm) | 3.86 EUR |
| Quarterly Revenue Growth (yoy) | 12.80% |
| Gross Profit (ttm) | 396.47M EUR |
| EBITDA | 101.38M EUR |
| Net Income Avi to Common (ttm) | 94.3M EUR |
| Diluted EPS (ttm) | 0.73 |
| Quarterly Earnings Growth (yoy) | -30.30% |
Balance Sheet
| Total Cash (mrq) | 465.06M EUR |
| Total Cash Per Share (mrq) | 4.58 EUR |
| Total Debt (mrq) | 575K EUR |
| Total Debt/Equity (mrq) | 0.11 EUR |
| Current Ratio (mrq) | 6.77 |
| Book Value Per Share (mrq) | 4.896 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 111.03M EUR |
| Levered Free Cash Flow (ttm) | 105.44M EUR |
Profile of Corcept Therapeutics Incorporated
| Country | Germany |
| State | CA |
| City | Menlo Park |
| Address | 149 Commonwealth Drive |
| ZIP | 94025 |
| Phone | 650 327 3270 |
| Website | https://www.corcept.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 299 |
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Q&A For Corcept Therapeutics Incorporated Stock
What is a current HTD.F stock price?
Corcept Therapeutics Incorporated HTD.F stock price today per share is 22.07 EUR.
How to purchase Corcept Therapeutics Incorporated stock?
You can buy HTD.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Corcept Therapeutics Incorporated?
The stock symbol or ticker of Corcept Therapeutics Incorporated is HTD.F.
Which industry does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated industry is Biotechnology.
How many shares does Corcept Therapeutics Incorporated have in circulation?
The max supply of Corcept Therapeutics Incorporated shares is 103.84M.
What is Corcept Therapeutics Incorporated Price to Earnings Ratio (PE Ratio)?
Corcept Therapeutics Incorporated PE Ratio is 25.07954600 now.
What was Corcept Therapeutics Incorporated earnings per share over the trailing 12 months (TTM)?
Corcept Therapeutics Incorporated EPS is 0.88 EUR over the trailing 12 months.
Which sector does the Corcept Therapeutics Incorporated company belong to?
The Corcept Therapeutics Incorporated sector is Healthcare.